Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.
Expert Rev Clin Pharmacol
; 14(10): 1289-1294, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1360277
ABSTRACT
PURPOSE:
We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients.METHODS:
We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our Institution from 20 May 2020 to 20 November 2020 with computer tomography (CT) detected PE at admission, treated with edoxaban after initial parenteral therapy. Clinical outcomes were compared between patients with and without ARDS at admission and between those with and without CT confirmed PE resolution.RESULTS:
50 patients were included. Mean follow-up was 42.5 ± 10 days. No baseline differences were found between patients with ARDS (30%) and those without ARDS at admission. Patients with PE resolution (84%) were younger (P = 0.03), had a shorter duration of fondaparinux therapy (9.9 ± 3.8 vs 15.8 ± 7.5 days; P = 0.0015) and length of hospitalization (36 ± 8 vs 46 ± 9 days P = 0.0023) compared with those without PE resolution. 2 patients experienced major bleedings. At multivariate analysis the time to edoxaban switch was the only predictor of the PE resolution (HR 0.92; 95% C.I. 0.86 to 0.99).CONCLUSION:
Edoxaban was an effective and safe treatment for acute PE in COVID-19 setting.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Embolism
/
Pyridines
/
Thiazoles
/
Factor Xa Inhibitors
/
SARS-CoV-2
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Expert Rev Clin Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
17512433.2021.1964359
Similar
MEDLINE
...
LILACS
LIS